H emifacial spasm (HFS) is relatively rare, with an estimated incidence of 0.8 per 100,000 persons/year and an estimated prevalence of 7.4 per 100,000 men and 14.5 per 100,000 women. 2 The disease typically begins as infrequent twitches of an eyelid that progress over time in intensity, frequency, and extent of involvement of the ipsilateral facial muscles. HFS may cause significant disability due to annoying and distracting twitches and forceful spasms, and also by the loss of binocular vision associated with involuntary eye closure. The greatest impact on the quality of life for many patients is the psychological and social impact of the facial disfigurement caused by the disorder. 15, 17 Surgical cure of HFS can be achieved with microvascular decompression (MVD) surgery, as pioneered by Jannetta in 1967, 12 and several series have demonstrated high rates of success and safety. 3, 4, [6] [7] [8] 10, 11, 13, 20, 21 The aim of this surgery is to alleviate culprit neurovascular compression (NVC) upon the facial nerve, most commonly at the facial root exit zone (fREZ). Only in rare cases is HFS caused by severe NVC of the cisternal portion of the facial nerve.
phasized, however, that culprit NVC may occur anywhere along the fREZ, which is defined as the entire length of the exposed centrally myelinated facial nerve fibers. 4, 15 These facial nerve fibers emerge from the pontomedullary sulcus, then remain adherent to the pontine surface for approximately 8 mm before separating from the brainstem, and then 2 mm further distal they transition from central to peripheral myelin before continuing as the cisternal portion that courses through the subarachnoid space. 4, 15, 22 These distinct segments of the fREZ may be identified as the root exit point (RExP), attached segment (AS), root detachment point (RDP), and transition zone (TZ), respectively. We have also observed that the failures of MVD surgery to alleviate HFS are commonly due to persistent culprit NVC somewhere upon this fREZ. In this study, we analyzed the findings at repeat MVD in patients with persistent or recurrent HFS, with the aim to identify factors that may improve surgical outcomes.
methods
All MVD surgeries performed by the senior author (A.M.K.) had been recorded in a prospective database, including 91 at the University of Pittsburgh Medical Center (1996) (1997) , 139 at the University of Calgary Foothills Hospital (1998) (1999) (2000) , and 615 at the University of Manitoba Health Sciences Centre (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) . Among these, 307 patients were referred for HFS, including the 12 patients who were referred after undergoing prior MVD surgery elsewhere and who are the subjects of this report. All these repeat MVD surgeries were performed between 1998 and 2012. Prior surgeries had been performed by 10 different surgeons in 5 Canadian provinces. Selection for repeat MVD surgery was based on an established HFS diagnosis and significant persistence or recurrence of spasms. Reoperation was offered if at least 1 year had passed since a prior unsuccessful MVD, or sooner if persistent NVC was clearly seen on MRI (Fig. 1) . No patients seeking repeat MVD surgery who met either of these criteria were denied surgery. Preoperative MRI or other diagnostic imaging was not otherwise used to select or exclude candidates for repeat MVD.
The intraoperative findings were determined from review of the dictated operative reports and operative diagrams completed by the senior author immediately following each of the reoperations. Clinical details and outcomes were determined from review of the hospital and clinic records. The most recent follow-up was performed by telephone interview with a standardized questionnaire administered by a research assistant. Contacted patients were also asked to provide a rating of their satisfaction with the repeat MVD surgery results, where a score of 0 was considered not at all satisfied and 10 was considered completely satisfied. The medical ethics committee at the University of Manitoba approved this study.
repeat mVd technique
The details of our standard MVD surgical technique for HFS have been previously published. 1, 4, 15 The lateral position was used, and our standard 5-to 8-cm linear retroauricular incision was opened utilizing either a portion of the preexisting incision line or a new one. Prior cranioplasty material was removed, in whole or in part, and additional bone was removed as required to clearly visualize the edge of the sigmoid sinus and the posterior fossa floor. The total required craniectomy used measured less than 3 × 2 cm. The dura was typically adherent to the underlying cerebellar convexity and opened with the aid of magnification. If no subdural CSF was encountered, CSF diversion was achieved with intraoperative lumbar puncture using a 25-gauge needle, performed by the anesthesiologist. The microsurgical exposure proceeded over the anterior-inferior aspect of the cerebellum, utilizing retraction applied with 5-F suction and microinstruments over a 1-cm-wide cottonoid overtop a rubber "slider." The cerebellum was elevated from the rootlets of lower cranial nerves IX-XI, and the arachnoid was opened sharply. The fREZ was exposed with gentle elevation of the cerebellar flocculus and choroid plexus, often utilizing a 3-mm tapered self-retaining retractor blade. The location of prior implant material was noted, and adhesions between the implant material and vessels, nerves, or brain were lysed as required. The culprit NVC on the fREZ was then identified, and offending vessels were mobilized away from the nerve and brainstem and then maintained in the new position with shredded Teflon felt (STF) implants (Bard Peripheral Vascular, Inc.). In all cases, intraoperative monitoring was used, including continuous brainstem auditory evoked responses and facial and endotracheal lead electromyography. More recently, we have also included routine monitoring of facial motor evoked potentials. 87 months), and the interval between the 2 surgeries was 6-312 months (mean 70 ± 89 months) ( Table 1) . Operative findings included prior craniectomies that did not extend to the sigmoid sinus and/or posterior fossa floor in 11 of 12 cases, such that additional bone removal was required. Intraoperative CSF diversion with lumbar puncture was used in 3 cases. Thorough exposure of the fREZ was achieved, and persistent NVC was alleviated in all cases.
Prior implant material from the first surgery was found in 11 of 12 cases and consisted of an Ivalon sponge (n = 2), unshredded Teflon felt (n = 1), or STF (n = 8). In 8 of 12 cases, the prior implant material was situated along the cisternal portion of the facial nerve in association with the anterior inferior cerebellar arteries (AICA) rather than at the fREZ (Fig. 2) . In these cases, the arachnoid over the fREZ had not been previously opened such that the dissection there was straightforward and not impeded by any adhesions related to prior surgery. Significant NVC was uncovered at the fREZ, alleviated by mobilization of the culprit vessels, and then the vessel was maintained in the new position with placement of the STF implants (Figs. 3 and 4). In Case 6, a 4-mm incidental aneurysm arising from the posterior inferior cerebellar artery (PICA) origin was contributing to compression on the attached segment of the fREZ, as discovered at repeat MVD surgery. The aneurysm was clipped and the vessels were mobilized such that culprit compression was alleviated. In 3 other cases (Cases 1, 2, and 9) where prior implant material was found in the region of the fREZ, persistent NVC was also discovered more proximally on the fREZ along the attached segment and RExP and was also alleviated at repeat MVD surgery.
No patient suffered severe complications such as death, stroke, facial paralysis, infection, or CSF leak. One patient (Case 9) suffered a transient worsening of preexisting mild postoperative facial paresis, which improved again to House-Brackmann Grade II, and the worsening of preexisting hearing deficit. These complications were associated with severe adherence of the prior unshredded Teflon felt implant to the cisternal portion of the facial and vestibulocochlear nerves found at repeat MVD. Another patient developed aseptic meningitis 10 days after repeat MVD that resolved without sequelae (Case 12).
Postoperative spasm relief was assessed by telephone interview for the 10 patients who could be reached at 91 ± 55 months (range 28-193), or from the most recent clinic notes for Cases 9 and 10 at 7 and 3 months, respectively. Complete spasm resolution was described by 11 of 12 patients, including 2 patients who noted only an occasional quiver of the eyelid; another patient (Case 2) reported over 75% reduction of spasms. No patients underwent additional surgery after repeat MVD. One patient (Case 7) received a single botulinum toxin injection at 5 months after surgery but prior to complete spasm resolution. Among those patients reached for the telephone questionnaire, the patient satisfaction ratings for the repeat MVD surgeries were all 9 or 10 out of 10. HFS, with spasm relief achieved in 86% to 97% of patients. 3, 4, [6] [7] [8] 10, 11, 15, 20, 24 Culprit NVC in HFS is almost always found at the fREZ. We and others have emphasized that this area comprises exposed centrally myelinated facial nerve fibers as they emerge at the pontomedullary sulcus (i.e., RExP), then ascend approximately 8 mm attached along the pontine surface (AS) before detaching from the brainstem (RDP) and finally transitioning to peripheral myelin a few millimeters more distal along the nerve (TZ) to the cisternal portion. 4, 15, 22 The majority of culprit NVC is found on the AS-fREZ. In 10% of patients, however, culprit NVC is exclusively at the RExP, an area immediately above the supraolivary fossa that may be difficult to visualize medial to the overlying glossopharyngeal nerve rootlets. 7 The best way to visualize the entire extent of the fREZ is by a subfollicular approach, which requires thorough dissection of the arachnoid between the cerebellum and lower cranial nerves IX-XI, then gentle upward retraction or elevation of the flocculus and often some of the associated choroid plexus that emerges from the foramen of Luschka. 9, 15 It is also important to account for all of the potential culprit vessels, which are often multiple and almost always arteries. It also bears emphasizing that the common association between the AICA and the cisternal portion of the facial nerve is not a usual cause of HFS. Although contact may be obvious and vessels may even course between tightly apposed cranial nerves VII and VIII, truly culprit NVC at the cisternal portion is seen in only 1% to 4% of cases, and in these cases only when the cisternal portion of the facial nerve is physically distorted in its course by this distal compression. 6, 9 MVD is no guarantee of HFS cure. In our own experience performing over 300 MVD procedures for HFS, nearly 10% of patients have undergone repeat MVD for persistent or recurrent HFS. Among these, persistent or recurrent NVC was usually discovered. This often was related to an elongated vertebral artery that had again shifted toward the fREZ despite previous mobilization and placement of the STF implants. For this reason, we have more recently adopted some form of sling technique whenever feasible for such large arteries. 1 The AICA has also been problematic in some cases when tethered by the pontine perforating vessels, limiting a wide mobilization away from the fREZ. At repeat surgery, the vessel may sometimes be better mobilized, although not at the expense of any perforators. As in prior reports, success rates have generally been lower than reported for initial surgery, 3, 16, 25 although we found that two-thirds of patients became spasm-free after our own repeat MVD. Similar to the results of our study, Barker and Jannetta did differentiate the results of surgery between patients treated initially by their own group versus other centers and found repeat MVD cure rates to be significantly higher in the latter. 3 Based on these observations, we undertook the current study with the aim of identifying potential factors that may help improve the results of MVD for HFS. It is noteworthy that the utilization of MVD for HFS is low in North America, with less than 10% of patients undergoing this surgery. This impacts the surgical caseload, such that few operations are done by many surgeons. In the United States, the median annual MVD caseload was 3 cases per year, and the majority of these operations were for trigeminal neuralgia rather than HFS, as reported by Kalkanis et al. 14 These authors also noted the average number of MVD procedures for HFS performed at nonfederal hospitals between 1996-2000 was 237 cases per year. Similarly, in Canada 40% of the 50 annual MVD procedures for HFS were performed at 12 neurosurgical centers, each with caseloads of less than 5 per year (Canadian Institutes of Health Information data 2004-2014). While gaining a large volume of experience and expertise in MVD for HFS is difficult given the rarity of this disease, attention to established techniques will enable favorable outcomes and potentially a raise in the surgical utilization rates.
conclusions
The keys to surgical success in performing MVD for HFS have been well illustrated and widely published. Exposure to the culprit NVC relies on a surgical corridor gained by bony removal to the limits of the sigmoid sinus laterally and posterior fossa floor inferiorly. A subfollicular approach to the fREZ generally provides adequate exposure and minimizes lateral retraction that may traumatize the cerebellum and vestibulocochlear nerve. It bears emphasis that the fREZ extends from its emergence at the pontomedullary sulcus and extends a couple of millimeters beyond the more superior detachment from the pons. All NVC along this 10 mm length should be alleviated, while vascular contact along the cisternal portion of the facial nerve root is generally incidental. MVD for HFS is effective when all NVC upon the fREZ is thoroughly alleviated. Optimization of surgical outcomes may lead to a greater utilization of this potentially curative treatment for HFS. 
